Matching the histopathology, hormone receptor status, and HER2 status of the parental tumor; generic variations retained after long-term expansion; providing in vitro drug screens; sensitive to drugs (e.g., afatinib and pictilisib) blocking the HER signaling pathway. The gene discussed is ERBB2; the disease is neoplasm.